Navelbine (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as a 20 mg tablet for oral use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and breast cancer, in adult patients as part of a chemotherapy regimen.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Vinorelbine is used in oncology to target rapidly dividing tumor cells in specific cancer types.

- Non‑small cell lung cancer: used as part of combination chemotherapy to inhibit tumor progression. - Breast cancer: employed in metastatic or advanced disease to control tumor growth. - Other solid tumours (clinical investigation): investigated as a therapeutic option in selected solid malignancies.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Neutropenia: reduced white blood cell count. - Constipation: decreased bowel movements. - Fatigue: general tiredness. - Alopecia: hair thinning or loss.

Serious or Rare Side Effects: - Severe neutropenia with fever: risk of infection. - Pulmonary toxicity: shortness of breath or cough. - Peripheral neuropathy: tingling or numbness in extremities. - Allergic reactions: rash, itching, or swelling. - Cardiac arrhythmia: irregular heart rhythm. - Hemorrhage: increased bleeding tendency.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for toxicity.

- Blood count monitoring: perform regular complete blood counts to detect neutropenia. - Hepatic function assessment: check liver enzymes as vinorelbine is metabolized hepatically. - Pre‑existing neuropathy: use caution in patients with nerve disorders. - Concomitant myelosuppressants: avoid or adjust doses to reduce bone‑marrow suppression. - Pregnancy and lactation: safety unknown; avoid use unless benefits outweigh risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase vinorelbine exposure and toxicity. - Concurrent myelosuppressive agents (e.g., cyclophosphamide): heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): potential for increased bleeding. - Other Vinca alkaloids: additive neurotoxicity risk.